SOMATIC MUTATIONS AT THE GLYCOPHORIN A LOCUS IN RADIATION EXPOSED INDIVIDUALS

受辐射个体中血型糖蛋白 A 基因座的体细胞突变

• 批准号: 3731573
• 负责人: RICHARD G LANGLOIS
• 金额: --
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3731573
• 关键词: Commonwealth of Independent States; DNA damage; bioassay; blood groups; cryopreservation; erythrocytes; fluorescent dye /probe; glycophorin; human genetic material tag; human population genetics; human tissue; ionizing radiation; monoclonal antibody; occupational hazard; radiation dosage; radiation genetics; radiation hazard; statistics /biometry; tissue /cell preparation

There are two primary objectives for the glycophorin A-based somatic mutation analysis project. The first objective is to determine the magnitude and types of somatic mutational damage in individuals due to radiation exposure from the Chernobyl nuclear power accident as measured by the glycophorin A (GPA) assay. Analysis will be performed on samples from individuals with both high- and moderate-dose exposures, and will include measurements of the frequency of both hemizygous N0 and homozygous NN variant erythrocytes. Measurements of the frequencies of somatic cell mutations at the GPA locus will be correlated with different indicators of genetic damage from other programs in the program project to provide a comprehensive analysis of genetic damage in these individuals. The second objective is to determine the utility of the GPA assay as a biodosimeter for large population studies of individuals where physical dosimetry information is not available. Measurements of the dose-response relationship, the minimum detectable dose, and the persistence of induced damage will be used to determine the utility of the GPA assay for dose assessment. Results from the GPA assay will be compared with the results from other biodosimeters in the program project to determine the relative sensitivity, cost, and reliability of the different methods.

基于血型糖蛋白A的体细胞免疫有两个主要目的。 突变分析项目 第一个目标是确定 个体的体细胞突变损伤的程度和类型， 切尔诺贝利核电站事故的辐射照射， 血型糖蛋白A（GPA）测定。 将对以下样本进行分析： 高剂量和中等剂量暴露的个人，并将包括 半合子N0和纯合子NN的频率测量 变异红细胞 体细胞频率的测量 GPA基因座的突变将与不同的指标相关， 基因损伤从其他程序中的程序项目，以提供一个 对这些人的遗传损伤进行全面分析。 第二个目的是确定GPA测定法作为一种生物测定法的实用性。 生物剂量计，用于对个人进行大规模人口研究， 没有剂量测定信息。 剂量反应测量 关系、最小可检测剂量和诱导的持续性 将使用损伤来确定GPA测定对剂量的效用 考核 将GPA测定的结果与 从程序项目中的其他生物剂量计， 不同方法的灵敏度、成本和可靠性。